Re: Analysis, relapse rate comparison to ABCR

[Guest guest]

> The LDN relapse rate was 0.2/year, or once in 5 years.

I have been trying to find references comparing all ABCR drugs on

relapse rates. Many of them state a reduction in relapses, rather

than per year, so I don't yet know how that compares. Here is a tudy,

but it is from 2001, and is missing Rebif. If anyone finds a better

one, let me know.

Average relapses per year:

Copaxone - 0.49;

Betaseron 0.55;

Avonex - 0.81;

Untreated - 1.02.

The Avonex reduction was not statistically significant

A prospective, open-label treatment trial to compare the effect of

IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate

(Copaxone) on the relapse rate in relapsing--remitting multiple

sclerosis: results after 18 months of therapy.

PMID: 11795454

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

cmd=Retrieve & db=PubMed & list_uids=11795454 & dopt=Abstract

[Guest guest]

These look about right, but the new 10 year copaxone data (as yet

available only in abstract form, shows a relapse rate of 0.2/year

after 4-10 years of copaxone.

More importantly, the LDN rate is better than that of any other

drug. The LDN rate must however be interpreted cautiously, as its

possible that some of the folks who had poor results never completed

the survey.

A

> > The LDN relapse rate was 0.2/year, or once in 5 years.

>

> I have been trying to find references comparing all ABCR drugs on

> relapse rates. Many of them state a reduction in relapses, rather

> than per year, so I don't yet know how that compares. Here is a

tudy,

> but it is from 2001, and is missing Rebif. If anyone finds a

better

> one, let me know.

>

> Average relapses per year:

> Copaxone - 0.49;

> Betaseron 0.55;

> Avonex - 0.81;

> Untreated - 1.02.

> The Avonex reduction was not statistically significant

>

> A prospective, open-label treatment trial to compare the effect of

> IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer

acetate

> (Copaxone) on the relapse rate in relapsing--remitting multiple

> sclerosis: results after 18 months of therapy.

> PMID: 11795454

>

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> cmd=Retrieve & db=PubMed & list_uids=11795454 & dopt=Abstract